[1]龚高进,许泽川,黄海汛△.血清微小核糖核酸-1297和微小核糖核酸-4458在骨肉瘤患者诊断及预后评估中的价值[J].中国中医骨伤科杂志,2024,32(04):68-72.[doi:10.20085/j.cnki.issn1005-0205.240414]
　GONG Gaojin,XU Zechuan,HUANG Haixun.The Value of Serum miR-1297 and miR-4458 in the Diagnosis and Prognosis Evaluation of Osteosarcoma Patients[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2024,32(04):68-72.[doi:10.20085/j.cnki.issn1005-0205.240414]
点击复制

血清微小核糖核酸-1297和微小核糖核酸-4458在骨肉瘤患者诊断及预后评估中的价值()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第32卷
期数:
2024年04期
页码:
68-72
栏目:
临床报道
出版日期:
2024-04-01

文章信息/Info

Title:
The Value of Serum miR-1297 and miR-4458 in the Diagnosis and Prognosis Evaluation of Osteosarcoma Patients
文章编号:
1005-0205(2024)04-0068-05
作者:
龚高进1; 许泽川1; 黄海汛1△
1成都医学院第二附属医院/核工业四一六医院(成都,610051)
Author(s):
GONG Gaojin1; XU Zechuan1; HUANG Haixun1△
1Second Affiliated Hospital of Chengdu Medical College(The 416th Hospital of Nuclear Industry),Chengdu 610051,China.
关键词:
骨肉瘤;  微小核糖核酸-1297;  微小核糖核酸-4458;  诊断;  预后
Keywords:
osteosarcoma;  microRNA-1297;  microRNA-4458;  diagnosis;  prognosis
分类号:
R738.1
DOI:
10.20085/j.cnki.issn1005-0205.240414
文献标志码:
B
摘要:
目的:探讨微小核糖核酸-1297(miR-1297)和微小核糖核酸-4458(miR-4458)在骨肉瘤患者血清中的表达水平,以及在诊断和预后评估中的价值。方法:收集2019年1月至2020年1月手术治疗的90例骨肉瘤患者(骨肉瘤组)作为研究对象,所有患者术后均进行3年的随访,根据生存情况将患者分为生存组(49例)和死亡组(41例); 另选取同期在本院体检的90例健康者作为对照组。比较各组血清miR-1297和miR-4458水平,多因素Logistic回归分析骨肉瘤患者预后的影响因素,用受试者工作特征(ROC)曲线分析血清miR-1297和miR-4458对骨肉瘤的诊断价值以及对预后的评估价值。结果:骨肉瘤组miR-1297和miR-4458水平低于对照组,差异有统计学意义(P<0.05)。miR-1297和miR-4458联合诊断骨肉瘤的曲线下面积(AUC)为0.863,敏感性为88.89%,特异性为65.56%,二者联合优于血清miR-1297和miR-4458各自单独诊断(Z二者联合-miR-1297=3.043,Z二者联合-miR-4458=3.826; P=0.002,<0.001)。肿瘤淋巴结转移(TNM)分期为ⅡB/Ⅲ期、发生远处转移的骨肉瘤患者血清miR-1297和miR-4458表达水平低于TNM分期为ⅡA期、未发生远处转移的患者,差异有统计学意义(P<0.05)。死亡组血清miR-1297和miR-4458表达水平低于生存组,差异有统计学意义(P<0.05)。血清miR-1297和miR-4458二者联合预测骨肉瘤患者预后的曲线下面积为0.951,敏感性为97.56%,特异性为83.67%,二者联合优于各自单独预测(Z二者联合-miR-1297=2.080,Z二者联合-miR-4458=2.530; P=0.038,0.011)。多因素Logistic回归分析结果显示,血清miR-1297和miR-4458表达水平高为骨肉瘤患者预后的保护因素,TNM分期晚、远处转移为危险因素(P<0.05)。结论:骨肉瘤患者血清miR-1297和miR-4458下调,二者联合对诊断骨肉瘤和预测患者预后有较好的参考价值。
Abstract:
Objective:To investigate the expression levels of microRNA-1297(miR-1297)and microRNA-4458(miR-4458)in the serum of patients with osteosarcoma,and their value in diagnosis and prognosis evaluation.Methods:90 patients with osteosarcoma(osteosarcoma group)who underwent surgical treatment from January 2019 to January 2020 were collected as research subjects,and all patients were followed up for 3 years after surgery.According to survival status,patients were grouped into survival group(49 cases)and death group(41 cases).Another 90 healthy individuals who underwent physical examination during the same period and matched the general information of osteosarcoma patients were regarded as the control group.The levels of serum miR-1297 and miR-4458 in each group were compared,multivariate Logistic regression was applied to analyze the influencing factors of prognosis in patients with osteosarcoma.Receiver operator characteristic(ROC)curve was applied to analyze the diagnostic value of serum miR-1297 and miR-4458 for osteosarcoma and their prognostic value.Results:The levels of miR-1297 and miR-4458 in the osteosarcoma group were reduced than those in control group.The differences were statistically significant(P<0.05).The area under the curve(AUC)of the combined diagnosis of miR-1297 and miR-4458 for osteosarcoma was 0.863,with a sensitivity of 88.89% and a specificity of 65.56%,the combination of the two was superior to the individual diagnosis of serum miR-1297 and miR-4458(Zcombination-miR-1297=3.043,Zcombination-miR-4458=3.826,P=0.002,<0.001).The expression levels of miR-1297 and miR-4458 in serum of osteosarcoma patients with TNM stage ⅡB/Ⅲ and distant metastasis were lower than those of patients with TNM stage ⅡA and no distant metastasis,the differences were statistically significant(P<0.05).The expression levels of serum miR-1297 and miR-4458 in the death group were lower than those in the survival group,the differences were statistically significant(P<0.05).The combined prediction of serum miR-1297 and miR-4458 for the prognosis of osteosarcoma had an AUC of 0.951,a sensitivity of 97.56%,and a specificity of 83.67%,the combination of the two was superior to their individual predictions(Zcombination-miR-1297=2.080,Zcombination-miR-4458=2.530,P=0.038,0.011).The results of multivariate Logistic regression analysis showed that serum miR-1297 and miR-4458 were protective factors for the prognosis of osteosarcoma patients,while TNM staging and distant metastasis were risk factors(P<0.05).Conclusion:Serum miR-1297 and miR-4458 are obviously down-regulated in patients with osteosarcoma,and the combination of the two has good reference value for diagnosing osteosarcoma and predicting prognosis.

参考文献/References:

[1] ZHAO X,WU Q,GONG X,et al.Osteosarcoma:a review of current and future therapeutic approaches[J].Biomed Eng Online,2021,20(1):1-14.
[2] YANG C,TIAN Y,ZHAO F,et al.Bone microenvironment and osteosarcoma metastasis[J].Int J Mol Sci,2020,21(19):1-17.
[3] ALIZADEH-FANALOU S,KHOSRAVI M,ALIAN F,et al.Dual role of microRNA-1297 in the suppression and progression of human malignancies[J].Biomed Pharmacother,2021,141(1):1-14.
[4] MOSAPOUR A,KARAMI TEHRANI F S,ATRI M.Differential expression of miR-1297,miR-3191-5p,miR-4435,and miR-4465 in malignant and benign breast tumors[J].Iran J Basic Med Sci,2020,23(8):1045-1052.
[5] MA Y,LI X,CHEN S,et al.MicroRNA-4458 suppresses migration and epithelial-mesenchymal transition via targeting HMGA1 in non-small-cell lung cancer cells[J].Cancer Manag Res,2019,11(1):637-649.
[6] 朱永刚,刘果,王含笑,等.MRI检查对骨肉瘤的诊断效能[J].癌症进展,2022,20(17):1829-1831.
[7] JIANG Z Y,LIU J B,WANG X F,et al.Current status and prospects of clinical treatment of osteosarcoma[J].Technol Cancer Res Treat,2022,21(1):1-12.
[8] MATSUOKA K,BAKIRI L,WOLFF L I,et al.Wnt signaling and Loxl2 promote aggressive osteosarcoma[J].Cell Res,2020,30(10):885-901.
[9] GHAFOURI-FARD S,MOGHADAM M H B,SHOOREI H,et al.The impact of non-coding RNAs on normal stem cells[J].Biomed Pharmacother,2021,142(1):1-14.
[10] SHENG B,LAI N S,YAO Y,et al.Early serum miR-1297 is an indicator of poor neurological outcome in patients with aSAH[J].Biosci Repm,2018,38(6):1-8.
[11] LIANG L,FENG L,WEI B.microRNA-1297 involves in the progression of oral squamous cell carcinoma through PTEN[J].Saudi J Biol Sci,2018,25(5):923-927.
[12] 齐乐,潘英,李素文,等.miR-1297下调AEG-1抑制胃癌细胞增殖和侵袭机制探讨[J].中华肿瘤防治杂志,2020,27(2):93-98.
[13] PAN X,LI H,TAN J,et al.miR-1297 suppresses osteosarcoma proliferation and aerobic glycolysis by regulating PFKFB2[J].Onco Targets Ther,2020,13(1):11265-11275.
[14] JIANG P,MAO L,LEI X,et al.miR-1297 inhibits osteosarcoma cell proliferation and growth by targeting CCND2[J].Am J Cancer Res,2022,12(7):3464-3478.
[15] QIU S,ZOU L,QIU R,et al.Circular RNA circHMCU promotes breast tumorigenesis through miR-4458/PGK1 regulatory cascade[J].Hereditas,2023,160(1):1-16.
[16] YANG X,WANG Y,PANG S,et al.LINC00665 promotes the progression of acute myeloid leukemia by regulating the miR-4458/DOCK1 pathway[J].Sci Rep,2021,11(1):1-16.
[17] WU M,TANG Y,HU G,et al.miR-4458 directly targets IGF1R to inhibit cell proliferation and promote apoptosis in hemangioma[J].Exp Ther Med,2020,19(4):3017-3023.
[18] ZHANG Y,SHI K,LIU H,et al.miR-4458 inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing the TGF-β signaling pathway via targeting TGFBR1[J].Acta Biochim Biophys Sin(Shanghai),2020,52(5):554-562.
[19] 张帅,魏巍.miRNA调控骨肉瘤肺转移的研究进展[J].临床与实验病理学杂志,2023,39(4):462-465.

备注/Memo

备注/Memo:
基金项目:2023年成都市医学科研课题(202304073353)
△通信作者 E-mail:wivtche915091@163.com
更新日期/Last Update: 2024-04-15